E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
advanced prostate cancer (locally advanced or metastatic) |
|
E.1.1.1 | Medical condition in easily understood language |
prostate cancer with tumor stage T3-T4 or metastatic |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Male diseases of the urinary and reproductive systems [C12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060862 |
E.1.2 | Term | Prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of the trial is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-85d] for serum testosterone in patients with advanced prostate cancer. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are:
• Time to castration [tcast] in patients with advanced prostate cancer
• Area under the curve [AUC1-169d] for testosterone
• Area under the curve [AUC85-169d] for testosterone
• Maximum concentration of serum testosterone [Cmax]
• Time to maximum concentration of serum testosterone [tmax]
• Number and percentage of patients attaining castrate level by day 29 and
maintaining castration until the end of the second dosing interval without showing
relevant escapes from castration
• Percentage of patients with castration levels of testosterone
• Course of PSA and testosterone levels and changes from baseline
• Evaluate the Visual Analogue Scale (VAS) for tumour-related pain, e.g. bone pain
• Safety profiles of IM and SC injections of triptorelin pamoate 11.25 mg
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
(1) Provision of written informed consent prior to any study related procedures.
(2) Male patients aged 18 years and older
(3) Histologically or cytologically proven prostate cancer, locally advanced or
metastatic, or rising PSA after failed local therapy, and the patient scheduled to
receive androgen deprivation therapy
- Definition of locally advanced: T3 or T4 or N1 with any T, M09
- Definition of metastatic: any T, any N, M1
(4) Serum testosterone levels ≥ 125 ng/dl (1.25 ng/ml, 1.25 ng/l, 4.3 nmol/l)
measured by any laboratory or on site within the previous 6 months or at study
start
(5) Karnofsky performance index > 70
(6) Expected survival ≥ 9 months
(7) Absence of other malignancy, other than dermatological, for the previous 5 years
|
|
E.4 | Principal exclusion criteria |
(1) Prior hormonal treatment for prostate cancer including finasteride, oestrogens or
a steroidal anti–androgen within the last 6 months preceding the study or
concomitant treatment with one or more of these substance(s)
(2) Prior hormonal treatment for prostate cancer including GnRH agonists or
antagonists within the last 12 months preceding the study or concomitant
treatment with one or more of these substance(s)
(3) Presence of another malignant neoplasm
(4) Prior hypophysectomy or adrenalectomy
(5) Patient who is scheduled to receive an orchiectomy during the course of this
study
(6) Any current use or within 6 months prior to treatment start of medications which
are known to affect the metabolism and/or secretion of androgenic hormones:
ketoconazole, aminoglutethimide, oestrogens and progesterone
(7) Use of corticosteroids, except topical applications
(8) Patient at risk of spinal cord compression or ureter obstruction
(9) Patient with abnormal baseline findings or any other medical condition(s) that, in
the opinion of the investigator, might jeopardise the subject’s safety or decrease
the chance of obtaining satisfactory data needed to achieve the objective(s) of
the study
(10) Patient has a history of hypersensitivity to the IMP or drugs with a similar
chemical structure
(11) Inability to give informed consent or to comply fully with the protocol
(12) Participation in another clinical trial within the last 30 days or simultaneous
participation in another clinical trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Area under the curve of testosterone serum concentration between D1 and D85 [AUC1-85d]. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day, Day 57, Day 85 |
|
E.5.2 | Secondary end point(s) |
Area under the curve [AUC85-169d] for testosterone |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Day 85, Day 87, Day 113, Day 141, Day 169 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | Yes |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 30 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will be considered to have finished after the last patient has completed the last visit in the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |